Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies

Ophthalmologica

Volumn 232, Issue 2, 2014, Pages 83-91

  Sorkin, Nir ^a   Loewenstein, Anat ^a   Habot Wilner, Zohar ^a   Goldstein, Michaela ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cystoid macular edema, persistent; Dexamethasone; Intravitreal injections; Ozurdex

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT; GLUCOCORTICOID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; FEMALE; HUMAN; MALE; OPTICS; RETINA MACULA CYSTOID EDEMA; RETINA VEIN OCCLUSION; RETINAL THICKNESS; RETREATMENT; UVEITIS; VISUAL ACUITY; CLASSIFICATION; DRUG EFFECTS; FOLLOW UP; INTERVENTION STUDY; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTERVENTION STUDIES; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 84925285766     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000360304     Document Type: Article

References (38)

1. Ehlers JP, Fekrat S: Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011; 56: 281-299.
2. Ferris FL 3rd, Patz A: Macular edema: a complication of diabetic retinopathy. Surv Ophthalmol 1984; 28(suppl):452-461.
3. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI: Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004; 88: 1159-1162.
4. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no. 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987; 27: 265-272.
5. Petrella RJ, Blouin J, Davies B, Barbeau M: Incidence and characteristics of patients with visual impairment due to macular edema secondary to retinal vein occlusion in a representative Canadian cohort. J Ophthalmol 2012; 2012: 723169.
6. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98: 766-785.
7. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98: 271-282.
8. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.e1035.
9. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405.
10. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY: Ranibizumab for macular edema following central retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-1133. e1121.
11. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112.e1101.
12. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE Study Group: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
13. Leopold IH: Nonsteroidal and steroidal antiinflammatory agents; in Sears ML, Tarkkanen A (eds): Surgical Pharmacology of the Eye. New York, Raven Press, 1985.
14. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C: Three-year followup of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245-251.
15. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; Group SSR: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-1114.
16. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, Group SSR: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-1128.
17. Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE: Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol 2011; 152: 441-448.e2.
18. van Kooij B, Rothova A, de Vries P: The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm 2006; 14: 73-85.
19. Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ, Yilmaz T, MacDonell RE, Quinones K, Foster CS: Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol 2009; 19: 622-629.
20. Pearson PA, Comstock TL, Ip M, Callanan D, Morse LS, Ashton P, Levy B, Mann ES, Eliott D: Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118: 1580-1587.
21. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460.
22. Sanford M: Fluocinolone acetonide intravitreal implant (Iluvien ® ): in diabetic macular oedema. Drugs 2013; 73: 187-193.
23. Arcinue CA, Ceron OM, Foster CS: A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013; 29: 501-507.
24. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A: Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond) 2013; 27: 65-71.
25. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31: 915-923.
26. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-317.
27. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553.
28. Zucchiatti I, Lattanzio R, Querques G, Querques L, Del Turco C, Cascavilla ML, Bandello F: Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012; 228: 117-122.
29. Miserocchi E, Modorati G, Pastore MR, Bandello F: Dexamethasone intravitreal implant: an effective adjunctive treatment for recalcitrant noninfectious uveitis. Ophthalmologica 2012; 228: 229-233.
30. Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M, Coi L, Turchetti P, Pacella F: Preliminary results of an intravitreal dexamethasone implant (Ozurdex ® ) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013; 7: 1423-1428.
31. Adan A, Pelegrin L, Rey A, Llorenc V, Mesquida M, Molins B, Rios J, Keller J: Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina 2013; 33: 1435-1440.
32. Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J: Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion. Retina 2013; 33: 1227-1231.
33. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B: Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 2013; 231: 141-146.
34. Sugar EA, Jabs DA, Altaweel MM, Lightman S, Acharya N, Vitale AT, Thorne JE: Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol 2011; 152: 1044-1052.
35. Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, Whitcup SM, Kowalski JW: Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012; 119: 1190-1198.
36. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; Group OGS: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.
37. Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group: Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009; 147: 1048-1054, 1054.
38. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F: Repeated intravitreal dexamethasone implant (Ozurdex ® ) for retinal vein occlusion. Ophthalmologica 2013; 229: 21-25.